SAN DIEGO, Oct. 3, 2017 /PRNewswire/ -- Shareholder rights
law firm Johnson Fistel, LLP has launched an investigation into
whether the board members of Dimension Therapeutics, Inc. (NASDAQ:
DMTX) ("Dimension") breached their fiduciary duties in connection
with the proposed sale of the Company to Ultragenyx Pharmaceutical
Inc.
On October 3, 2017, Dimension
announced that it had signed a definitive merger agreement with
Ultragenyx. Terms of the deal call for shareholders to receive
$6.00 per share for each share of
Dimension stock they own.
The investigation concerns whether the Dimension board failed to
satisfy its duties to the Company shareholders, including whether
the board adequately pursued alternatives to the acquisition and
whether the board obtained the best price possible for Dimension
shares of common stock.
If you are a shareholder of Dimension and believe the
proposed buyout price is too low or you're interested in learning
more about the investigation or your legal rights and remedies,
please contact lead analyst Jim
Baker (jimb@johnsonfistel.com) at 619-814-4471. If
emailing, please include a phone number.
About Johnson Fistel,
LLP:
Johnson Fistel, LLP is a nationally
recognized shareholder rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonfistel.com. Attorney advertising. Past results do
not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com
View original
content:http://www.prnewswire.com/news-releases/dimension-dmtx-alert-johnson-fistel-investigates-proposed-sale-of-dimension-therapeutics-inc-are-shareholders-getting-a-fair-price-300529946.html
SOURCE Johnson Fistel, LLP
